Publication:
Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.

Simple item page
dc.contributor.authorTurkeli, Mehmet
dc.contributor.authorAldemir, Mehmet Naci
dc.contributor.authorCayir, Kerim
dc.contributor.authorSimsek, MELİH
dc.contributor.authorBilici, Mehmet
dc.contributor.authorTekin, Salim Basol
dc.contributor.authorYildirim, Nilgun
dc.contributor.authorBilen, Nurhan
dc.contributor.authorMakas, Ibrahim
dc.contributor.institutionauthorŞİMŞEK, MELİH
dc.date.accessioned2021-04-05T20:59:18Z
dc.date.available2021-04-05T20:59:18Z
dc.date.issued2015-01-01T00:00:00Z
dc.identifier.citationTurkeli M., Aldemir M. N. , Cayir K., Simsek M., Bilici M., Tekin S. B. , Yildirim N., Bilen N., Makas I., -Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.-, Asian Pacific journal of cancer prevention : APJCP, cilt.16, ss.985-9, 2015
dc.identifier.doi10.7314/apjcp.2015.16.3.985
dc.identifier.scopus84929334115
dc.identifier.urihttp://hdl.handle.net/20.500.12645/28672
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleEfficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
dc.typeArticle
dspace.entity.typePublication
local.avesis.idbd4cfc36-d301-4efc-a1d9-dd4b34036a14
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication037fbf0b-fefb-4173-9f93-478d96e2926f
relation.isAuthorOfPublication.latestForDiscovery037fbf0b-fefb-4173-9f93-478d96e2926f
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c

Files

Collections

Silinecekler